MTOR and small cell lung carcinoma: Umemura et al. demonstrated that the survival of cisplatin-resistant SCLC cell lines could be suppressed using the new PI3K/mTOR dual inhibitor (BEZ235); however, not all SCLC cell lines harboring alterations in the PI3K/AKT/mTOR pathway exhibited the same degree of sensitivity to BEZ235 [10].